Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Psychiatry ; 22(10): 1422-1430, 2017 10.
Article in English | MEDLINE | ID: mdl-27698427

ABSTRACT

The brain circuits underlying behavioral fear have been extensively studied over the last decades. Although the vast majority of experimental studies assess fear as a transient state of apprehension in response to a discrete threat, such phasic states of fear can shift to a sustained anxious apprehension, particularly in face of diffuse cues with unpredictable environmental contingencies. Unpredictability, in turn, is considered an important variable contributing to anxiety disorders. The networks of the extended amygdala have been suggested keys to the control of phasic and sustained states of fear, although the underlying synaptic pathways and mechanisms remain poorly understood. Here, we show that the endocannabinoid system acting in synaptic circuits of the extended amygdala can explain the fear response profile during exposure to unpredictable threat. Using fear training with predictable or unpredictable cues in mice, combined with local and cell-type-specific deficiency and rescue of cannabinoid type 1 (CB1) receptors, we found that presynaptic CB1 receptors on distinct amygdala projections to bed nucleus of the stria terminalis (BNST) are both necessary and sufficient for the shift from phasic to sustained fear in response to an unpredictable threat. These results thereby identify the causal role of a defined protein in a distinct brain pathway for the temporal development of a sustained state of anxious apprehension during unpredictability of environmental influences, reminiscent of anxiety symptoms in humans.


Subject(s)
Fear/physiology , Receptor, Cannabinoid, CB1/metabolism , Amygdala/metabolism , Amygdala/physiology , Animals , Anxiety/etiology , Anxiety Disorders/etiology , Anxiety Disorders/metabolism , Cannabinoids/metabolism , Cannabinoids/pharmacology , Cues , Endocannabinoids/metabolism , Male , Mice , Receptor, Cannabinoid, CB1/physiology , Reflex, Startle/physiology , Septal Nuclei/physiology
2.
J Psychopharmacol ; 26(1): 23-39, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21768162

ABSTRACT

Evidence for the involvement of the endocannabinoid system (ECS) in anxiety and fear has been accumulated, providing leads for novel therapeutic approaches. In anxiety, a bidirectional influence of the ECS has been reported, whereby anxiolytic and anxiogenic responses have been obtained after both increases and decreases of the endocannabinoid tone. The recently developed genetic tools have revealed different but complementary roles for the cannabinoid type 1 (CB1) receptor on GABAergic and glutamatergic neuronal populations. This dual functionality, together with the plasticity of CB1 receptor expression, particularly on GABAergic neurons, as induced by stressful and rewarding experiences, gives the ECS a unique regulatory capacity for maintaining emotional homeostasis. However, the promiscuity of the endogenous ligands of the CB1 receptor complicates the interpretation of experimental data concerning ECS and anxiety. In fear memory paradigms, the ECS is mostly involved in the two opposing processes of reconsolidation and extinction of the fear memory. Whereas ECS activation deteriorates reconsolidation, proper extinction depends on intact CB1 receptor signalling. Thus, both for anxiety and fear memory processing, endocannabinoid signalling may ensure an appropriate reaction to stressful events. Therefore, the ECS can be considered as a regulatory buffer system for emotional responses.


Subject(s)
Anxiety/metabolism , Cannabinoid Receptor Modulators/metabolism , Endocannabinoids , Fear/physiology , Habituation, Psychophysiologic/physiology , Memory/physiology , Animals , Anxiety/psychology , Fear/psychology , Humans , Receptor, Cannabinoid, CB1/metabolism
3.
Br J Pharmacol ; 123(6): 1182-8, 1998 Mar.
Article in English | MEDLINE | ID: mdl-9559903

ABSTRACT

1. The effects of 5-hydroxytryptamine (5-HT) in rat cardiac preparations were studied. 5-HT up to 10 microM failed to affect contractility in papillary muscles. However, in electrically driven (1 Hz) left atria 5-HT exerted a positive inotropic effect that started at 1 microM and attained its maximum at 10 microM (312+/-50% of predrug value, n=8). 2. 5-HT 10 microM stimulated the content of inositol-1,4,5-trisphosphate but not of cyclic AMP in rat left atria. 3. Plasma and serum levels of 5-HT amounted to about 0.3 microM and 15 microM, respectively. 4. The selective 5-HT4 receptor antagonists GR 125487 (10 nM and 1 microM) and SB 203186 (1 microM) did not attenuate the positive inotropic effect of 5-HT in rat left atria. In contrast, the 5-HT2 receptor antagonist ketanserin (5 nM, 50 nM, 1 microM) resulted in a concentration-dependent diminution of the positive inotropic effect of 5-HT in rat left atria. 5. Reverse transcriptase polymerase chain reaction with specific primers detected mRNA of the 5-HT2A receptor in rat atria and ventricles, while expression of the 5-HT4 receptor was confined to atria. 6. It is suggested that the positive inotropic effect of 5-HT in electrically driven rat left atria is mediated by ketanserin-sensitive 5-HT2A receptors and not through 5-HT4 receptors.


Subject(s)
Heart Atria/drug effects , Serotonin/pharmacology , Animals , Atrial Function , Blotting, Southern , Cyclic AMP/metabolism , Heart Atria/metabolism , In Vitro Techniques , Indoles/pharmacology , Inositol 1,4,5-Trisphosphate/pharmacology , Male , Muscle Contraction/drug effects , Polymerase Chain Reaction , RNA, Messenger/genetics , Rats , Rats, Wistar , Receptor, Serotonin, 5-HT2A , Receptors, Serotonin/genetics , Receptors, Serotonin, 5-HT4 , Serotonin/blood , Serotonin Antagonists/pharmacology , Sulfonamides/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...